. 2018 Apr 12;19:65. doi: 10.1186/s12931-018-0770-7

Table 2.

Pharmacological characteristics of BDP and FF administered as monocomponents on the histaminergic contractile tone of medium bronchi and small airways (PCLS) in non-sensitized and passively sensitized tissues

	BDP				FF
	Medium bronchi		Bronchioles		Medium bronchi		Bronchioles
	E_max	pEC₅₀	E_max	pEC₅₀	E_max	pEC₅₀	E_max	pEC₅₀
Non-sensitized	< 20%	NC	< 20%	NC	97.00 ± 2.77%	8.26 ± 0.07	72.03% ± 4.34^#	7.13 ± 0.11^#
Passively sensitized	< 20%	NC	< 20%	NC	94.96 ± 1.22%	8.89 ± 0.04***	105.30%***	7.52 ± 0.09*^#

*P < 0.05 and ***P < 0.001 vs. non-sensitized airways of equal diameter, ^#P < 0.001 vs. medium bronchi undergoing the same treatment (statistical significance assessed by t-test). BDP Beclomethasone dipropionate, EC₅₀ The concentration inducing 50% E_max, E_max maximal effect, FF Formoterol fumarate, NC Not calculable, PCLS Precision cut lung slices, pEC₅₀ -LogEC₅₀